

# Resource Summary Report

Generated by [RRID](#) on Aug 3, 2026

## Human CCL5/RANTES Antibody

RRID:AB\_354440

Type: Antibody

---

### Proper Citation

R and D Systems Cat# AF-278-NA, RRID:AB\_354440

---

### Antibody Information

**URL:** [http://antibodyregistry.org/AB\\_354440](http://antibodyregistry.org/AB_354440)

**Proper Citation:** R and D Systems Cat# AF-278-NA, RRID:AB\_354440

**Target Antigen:** CCL5/RANTES

**Host Organism:** Goat

**Clonality:** polyclonal

**Comments:** Applications: Western Blot, Simple Western, Immunohistochemistry, Neutralization, Immunocytochemistry

**Antibody Name:** Human CCL5/RANTES Antibody

**Description:** This polyclonal targets CCL5/RANTES

**Target Organism:** Human

**Antibody ID:** AB\_354440

**Vendor:** R and D Systems

**Catalog Number:** AF-278-NA

**Alternative Catalog Numbers:** AF-278-SP

**Record Creation Time:** 20250820T011216+0000

**Record Last Update:** 20250820T101813+0000

---

### Ratings and Alerts

No rating or validation information has been found for Human CCL5/RANTES Antibody.

No alerts have been found for Human CCL5/RANTES Antibody.

---

## Data and Source Information

**Source:** [Antibody Registry](#)

---

## Usage and Citation Metrics

We found 5 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [RRID](#) .

Le Pelletier L, et al. (2025) C-C chemokine ligand 5 from women subcutaneous adipose tissue has a central role in vascular aging. Cardiovascular diabetology, 24(1), 295.

Xiong Z, et al. (2024) Cancer-associated fibroblasts promote enzalutamide resistance and PD-L1 expression in prostate cancer through CCL5-CCR5 paracrine axis. iScience, 27(5), 109674.

Jang HJ, et al. (2023) A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy. Clinical cancer research : an official journal of the American Association for Cancer Research, 29(11), 2052.

Jiang SS, et al. (2023) Fusobacterium nucleatum-derived succinic acid induces tumor resistance to immunotherapy in colorectal cancer. Cell host & microbe, 31(5), 781.

Topper MJ, et al. (2023) Derivation of CD8+ T??cell infiltration potentiators in non-small-cell lung cancer through tumor microenvironment analysis. iScience, 26(7), 107095.